These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30363900)

  • 1. Electrochemical Skin Conductance as a Marker of Painful Oxaliplatin-Induced Peripheral Neuropathy.
    Delmotte JB; Tutakhail A; Abdallah K; Reach P; D'Ussel M; Deplanque G; Beaussier H; Coudoré F
    Neurol Res Int; 2018; 2018():1254602. PubMed ID: 30363900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet-NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial.
    Balayssac D; Ferrier J; Pereira B; Gillet B; Pétorin C; Vein J; Libert F; Eschalier A; Pezet D
    BMJ Open; 2015 Apr; 5(4):e007479. PubMed ID: 25833669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin Neuropathy: Predictive Values of Skin Biopsy, QST and Nerve Conduction.
    Krøigård T; Svendsen TK; Wirenfeldt M; Schrøder HD; Qvortrup C; Pfeiffer P; Gaist D; Sindrup SH
    J Neuromuscul Dis; 2021; 8(4):679-688. PubMed ID: 33814460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electrochemical skin conductance to detect sudomotor dysfunction, peripheral neuropathy and the risk of foot ulceration among Saudi patients with diabetes mellitus.
    Sheshah E; Madanat A; Al-Greesheh F; Al-Qaisi D; Al-Harbi M; Aman R; Al-Ghamdi AA; Al-Madani K
    J Diabetes Metab Disord; 2015; 15():29. PubMed ID: 27500133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is quantitative sensory testing helpful in the management of oxaliplatin neuropathy? a two-year clinical study.
    Delmotte JB; Beaussier H; Auzeil N; Massicot F; Laprévote O; Raymond E; Coudoré F
    Cancer Treat Res Commun; 2018; 17():31-36. PubMed ID: 30343217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer.
    Griffith KA; Zhu S; Johantgen M; Kessler MD; Renn C; Beutler AS; Kanwar R; Ambulos N; Cavaletti G; Bruna J; Briani C; Argyriou AA; Kalofonos HP; Yerges-Armstrong LM; Dorsey SG
    J Pain Symptom Manage; 2017 Nov; 54(5):701-706.e1. PubMed ID: 28743660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quick, non-invasive and quantitative assessment of small fiber neuropathy in patients receiving chemotherapy.
    Saad M; Psimaras D; Tafani C; Sallansonnet-Froment M; Calvet JH; Vilier A; Tigaud JM; Bompaire F; Lebouteux M; de Greslan T; Ceccaldi B; Poirier JM; Ferrand FR; Le Moulec S; Huillard O; Goldwasser F; Taillia H; Maisonobe T; Ricard D
    J Neurooncol; 2016 Apr; 127(2):373-80. PubMed ID: 26749101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup.
    Kerckhove N; Busserolles J; Stanbury T; Pereira B; Plence V; Bonnetain F; Krakowski I; Eschalier A; Pezet D; Balayssac D
    BMJ Open; 2019 Jun; 9(6):e027770. PubMed ID: 31182448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological Mechanisms and Preventive Strategies of Oxaliplatin-Induced Peripheral Neuropathy.
    Egashira N
    Front Pain Res (Lausanne); 2021; 2():804260. PubMed ID: 35295491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrochemical Skin Conductance Correlates with Skin Nerve Fiber Density.
    Novak P
    Front Aging Neurosci; 2016; 8():199. PubMed ID: 27605912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Prospective Study of Chronic Oxaliplatin-Induced Neuropathy in Patients with Colon Cancer: Long-Term Outcomes and Predictors of Severe Oxaliplatin-Induced Neuropathy.
    Kim SH; Kim W; Kim JH; Woo MK; Baek JY; Kim SY; Chung SH; Kim HJ
    J Clin Neurol; 2018 Jan; 14(1):81-89. PubMed ID: 29629544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temporal, Location- and Symptom-Specific Likelihood of Patient-Reported Sensory Symptoms Related to Oxaliplatin-Induced Peripheral Neuropathy (OIPN) in Patients Receiving Oxaliplatin for Three Months.
    Zahrieh D; Satele D; Smith EML; Loprinzi CL; Le-Rademacher J
    Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment.
    Kang L; Tian Y; Xu S; Chen H
    J Neurol; 2021 Sep; 268(9):3269-3282. PubMed ID: 32474658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Normative Values for Electrochemical Skin Conductance Measurements for Quantitative Assessment of Sudomotor Function in Healthy Indian Adults.
    Shivaprasad C; Goel A; Vilier A; Calvet JH
    Indian J Endocrinol Metab; 2018; 22(1):57-61. PubMed ID: 29535938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laser acupuncture attenuates oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancer: a pilot prospective cohort study.
    Hsieh YL; Chou LW; Hong SF; Chang FC; Tseng SW; Huang CC; Yang CH; Yang CC; Chiu WF
    Acupunct Med; 2016 Oct; 34(5):398-405. PubMed ID: 27613370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in chemotherapy-induced peripheral neuropathy, disturbance in activities of daily living, and depression following chemotherapy in patients with colorectal cancer: A prospective study.
    Oh PJ; Lee JR; Kim SK; Kim JH
    Eur J Oncol Nurs; 2020 Feb; 44():101676. PubMed ID: 31751847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early identification of peripheral neuropathy based on sudomotor dysfunction in Mexican patients with type 2 diabetes.
    Carbajal-Ramírez A; Hernández-Domínguez JA; Molina-Ayala MA; Rojas-Uribe MM; Chávez-Negrete A
    BMC Neurol; 2019 May; 19(1):109. PubMed ID: 31151430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study.
    Attal N; Bouhassira D; Gautron M; Vaillant JN; Mitry E; Lepère C; Rougier P; Guirimand F
    Pain; 2009 Aug; 144(3):245-252. PubMed ID: 19457614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-dependent discrepancies between physician-assessed and patient-reported oxaliplatin-induced peripheral neuropathy in patients with metastatic colorectal cancer who received mFOLFOX6 plus bevacizumab: a post hoc analysis (WJOG4407GSS2).
    Miura Y; Ando M; Yamazaki K; Hironaka S; Boku N; Muro K; Hyodo I
    Support Care Cancer; 2021 Jul; 29(7):3715-3723. PubMed ID: 33200233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrochemical Skin Conductance by Sudoscan in Non-Dialysis Chronic Kidney Disease Patients.
    Chiu LT; Lin YL; Wang CH; Hwu CM; Liou HH; Hsu BG
    J Clin Med; 2023 Dec; 13(1):. PubMed ID: 38202194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.